Literature DB >> 5025779

Hyperuricemia due to ethambutol.

A E Postlethwaite, A G Bartel, W N Kelley.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1972        PMID: 5025779     DOI: 10.1056/NEJM197204062861407

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  8 in total

1.  Two cases of ethambutol nephrotoxicity.

Authors:  J Collier; A M Joekes; P E Philalithis; F D Thompson
Journal:  Br Med J       Date:  1976-11-06

2.  Adverse effects of antituberculosis drugs.

Authors:  D J Girling
Journal:  Drugs       Date:  1982 Jan-Feb       Impact factor: 9.546

3.  Pyrazinamide-induced hyperuricemia.

Authors:  Antony Q Pham; Anh Doan; Matt Andersen
Journal:  P T       Date:  2014-10

Review 4.  Lowering and Raising Serum Urate Levels: Off-Label Effects of Commonly Used Medications.

Authors:  Nicole Leung; Kevin Yip; Michael H Pillinger; Michael Toprover
Journal:  Mayo Clin Proc       Date:  2022-07       Impact factor: 11.104

5.  Novel Antibacterial Activity of Febuxostat, an FDA-Approved Antigout Drug against Mycobacterium tuberculosis Infection.

Authors:  Lee-Han Kim; Soon Myung Kang; Jake Whang; Kee Woong Kwon; Sung Jae Shin
Journal:  Antimicrob Agents Chemother       Date:  2022-08-30       Impact factor: 5.938

6.  Interaction of Ethambutol with human organic cation transporters of the SLC22 family indicates potential for drug-drug interactions during antituberculosis therapy.

Authors:  Xiaolei Pan; Li Wang; Dirk Gründemann; Douglas H Sweet
Journal:  Antimicrob Agents Chemother       Date:  2013-08-05       Impact factor: 5.191

Review 7.  Treatment of tuberculous infection and disease in children: the North American perspective.

Authors:  C D Stowe; R F Jacobs
Journal:  Paediatr Drugs       Date:  1999 Oct-Dec       Impact factor: 3.930

8.  Identification of Febuxostat as a New Strong ABCG2 Inhibitor: Potential Applications and Risks in Clinical Situations.

Authors:  Hiroshi Miyata; Tappei Takada; Yu Toyoda; Hirotaka Matsuo; Kimiyoshi Ichida; Hiroshi Suzuki
Journal:  Front Pharmacol       Date:  2016-12-27       Impact factor: 5.810

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.